TNF and inflammatory bowel disease: Recent advances that have revolutionized IBD treatment include blocking antibodies against pro‐inflammatory cytokines such as TNF (e.g. infliximab or adalimumab), IL‐12, and IL‐23 (ustekinumab) and against integrins such as vedolizumab (Neurath, 2019).